Proteins

Items 361-370 of 918

per page
Set Descending Direction
  1. Fc (human) IgG4 Control (rec.)
    CHI-HF-210IG4
    CHI-HF-210IG4-C100100 µg
    CHF 390.00
  2. Fc (human):BAFF (human) (rec.)
    AG-40B-0120
    AG-40B-0120-C01010 µg
    CHF 230.00
    AG-40B-0120-30103 x 10 µg
    CHF 460.00
    AG-40B-0120-C500500 µg
    CHF 2'400.00
    Restoration of the splenic T and B cell architecture in Fc-BAFF injected BAFFdeficient mice. BAFF deficient mice were injected at day 0 with 100mg BAFF (human):Fc (human) (AG-40B-0120) intravenously and at day 14 with 50mg BAFF (human):Fc (human) intraper
  3. Fc (human):CD137L, Soluble (human) (rec.)
    AG-40B-0173
    AG-40B-0173-C01010 µg
    CHF 265.00
    AG-40B-0173-30103 x 10 µg
    CHF 530.00
    Fc (human):CD137L, Soluble (human) (rec.) (AG-40B-0173) binds to human CD137. Method: CD137 (human):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations of Fc (human):CD137L, Soluble (human) (AG-40B-
  4. Fc (human):Dectin-1 (mouse) (rec.)
    AG-40B-0138
    AG-40B-0138-C05050 µg
    CHF 350.00
  5. Fc (human):Dectin-2 (mouse) (rec.)
    AG-40B-0139
    AG-40B-0139-C05050 µg
    CHF 350.00
  6. Fc (human):FasL, Soluble (human) (rec.)
    AG-40B-0132
    AG-40B-0132-C01010 µg
    CHF 335.00
    AG-40B-0132-30103 x 10 µg
    CHF 670.00
    Oligomerisation of FasL (h) efficiently triggers Jurkat cell death.Method: Jurkat cells were treated O/N with the indicated concentrations of MegaFasL, Soluble (human) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Pr
  7. Fc (human):FGL1 (human) (rec.)
    AG-40B-0184
    AG-40B-0184-C01010 µg
    CHF 240.00
    AG-40B-0184-30103 x 10 µg
    CHF 480.00
    AG-40B-0184-C100100 µg
    CHF 1'140.00
  8. Fc (human):FGL1 (mouse) (rec.)
    AG-40B-0185
    AG-40B-0185-C01010 µg
    CHF 240.00
    AG-40B-0185-30103 x 10 µg
    CHF 480.00
    AG-40B-0185-C100100 µg
    CHF 1'140.00
  9. Fc (human):FLT3 Ligand (human) (rec.)
    AG-40B-0119
    AG-40B-0119-C01010 µg
    CHF 240.00
    AG-40B-0119-30103 x 10 µg
    CHF 480.00
    AG-40B-0119-C100100 µg
    CHF 960.00
    Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 μg daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice.
  10. Fc (human):FNDC4 (rec.)
    AG-40B-0213
    AG-40B-0213-C05050 µg
    CHF 330.00
    AG-40B-0213-30503 x 50 µg
    CHF 660.00

Items 361-370 of 918

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.